Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genflow Biosciences Plc ( (GB:GENF) ) has shared an announcement.
Genflow Biosciences Plc has announced significant progress in its lead programs, GF-1002 and GF-1004. The company is advancing key development activities for GF-1002, preparing for European Clinical Trial Authorisation by collaborating with Exothera for Chemistry, Manufacturing, and Controls work to ensure GMP standards. Concurrently, pivotal efficacy studies are being conducted with Physiogenex and Accelera to evaluate GF-1002 in MASH. Additionally, Genflow has amended the protocol for its GF-1004 clinical trial in aged dogs to specify intravenous dose rates, enhancing safety and efficacy assessments. These developments reflect the company’s strategic positioning to accelerate its programs through expected non-dilutive funding, partnerships, and supportive regulatory conditions.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is a biotechnology company focused on pioneering gene therapies to slow down the aging process. The company aims to promote longer and healthier lives while addressing the impacts of an aging global population. Genflow’s lead compound, GF-1002, involves the delivery of a centenarian variant of the SIRT6 gene, showing promising preclinical results.
Average Trading Volume: 5,343,043
Technical Sentiment Signal: Sell
For a thorough assessment of GENF stock, go to TipRanks’ Stock Analysis page.